Decibel Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Decibel Therapeutics Inc (DBTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Decibel Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Decibel Therapeutics Inc | - | - | - | Yes |
| Competitors combined (60) | ||||
| High-Confidence Competitors (42) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DBTX Stock Performance relative to its Competitors
DBTX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Rallybio Corporation | 282.9% | Outperformed |
| 2 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Merus N v | 282.9% | Outperformed |
| 4 | Edgewise Therapeutics inc | 282.9% | Outperformed |
| 5 | Boundless Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Decibel Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Decibel Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Decibel Therapeutics Inc |
122.84 | - |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Teva Pharmaceutical Industries Limited |
50,407.63 | 14,020.00 |
 Roivant Sciences Ltd |
28,023.80 | 7.53 |
 Viatris Inc |
23,161.30 | 14,737.30 |
| SUBTOTAL | 705,480.09 | 126,558.11 |
Sign in to see all competitors of Decibel Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Decibel Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Decibel Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Decibel Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Allarity Therapeutics Inc | Company report | 85% |
| Omniab Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Adverum Biotechnologies Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Zai Lab Limited | Company report | 85% |
| INVO | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Alimera Sciences Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Unity Biotechnology Inc | Company report | 85% |
| Eyepoint Inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Kalvista Pharmaceuticals Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Biocon Biologics Ltd | Company report | 85% |
| Our Marketed Products | Company report | 85% |
| FENCF | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Canton Strategic Holdings Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Fennec Pharmaceuticals Inc | Company report | 85% |
| Otonomy Inc | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Ocular Therapeutix Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Cymabay Therapeutics Inc | Company report | 85% |
| Karyopharm Therapeutics Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Argenx Se | Company report | 85% |
| Neurogene Inc | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Madrigal Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Rocket Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Decibel Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Decibel Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
| Harmony Biosciences Holdings inc | Rare Neurological Diseases Segment 100.00 % |
| Precigen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Decibel Therapeutics Inc .
Decibel Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Decibel Therapeutics Inc | 123 | - | -1,584,800 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Teva Pharmaceutical Industries Limited | 50,408 | 412,960 | 14,963 |
| Roivant Sciences Ltd | 28,024 | 10,043 | -552,803 |
| Viatris Inc | 23,161 | 491,243 | -13,690 |
| PEERS TOTAL | 705,357 | 804,749 | 124,880 |
Sign in to see all peers for Decibel Therapeutics Inc .
Decibel Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Decibel Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 1.2x | 4.3x | -3.0x |
| Return on Equity | -84.03 % | industry aggregate | -94.97 % |
| Return on Invested Capital | -37.62 % | -9.83 % (avg) | -27.79 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Decibel Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 95.0 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (55.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-15.7% annualized).
Methodology: see Methodology: SWOT Analysis.
Decibel Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Decibel Therapeutics Inc | 1.56 | 4.30 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| Roivant Sciences Ltd | 12.24 | 22.90 | - |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
Sign in to see all peers for Decibel Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Decibel Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Decibel Therapeutics Inc | Q2 2023 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| Roivant Sciences Ltd | Q2 2026 | -33.5 % | - |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +8.7 % | +22.0 % |
Sign in to see all peers for Decibel Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Decibel Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Decibel Therapeutics Inc | Q2 2023 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| Roivant Sciences Ltd | Q2 2026 | - | -89.6 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
Sign in to see all peers for Decibel Therapeutics Inc .
Decibel Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Decibel Therapeutics Inc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| Roivant Sciences Ltd | - | - | - |
| Viatris Inc | - | - | - |
Sign in to see all peers for Decibel Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Decibel Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Decibel Therapeutics Inc | - | - |
| Novartis Ag | 22.73 | 5.61 |
| Amgen Inc | 28.60 | 6.57 |
| Teva Pharmaceutical Industries Limited | 57.07 | 3.60 |
| Roivant Sciences Ltd | - | 3,720.63 |
| Viatris Inc | - | 1.57 |
| PEERS AVERAGE | 36.04 | 5.57 |
Sign in to see all peers for Decibel Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.